Targeting tumors with hypoxia-activated cytotoxins

Frontiers in Bioscience

Volumn 12, Issue 9, 2007, Pages 3483-3501

  Ahn, G One ^a   Brown, Martin ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Bioreductive prodrug; Hypoxia; Radiation activated prodrug; Radiosensitizer; Review; Tumor

Indexed keywords

BACTERIA (MICROORGANISMS); CLOSTRIDIA;

CYTOTOXIN; PRODRUG; RADIOSENSITIZING AGENT;

ANOXIA; GENE THERAPY; HUMAN; METABOLISM; NEOPLASM; REVIEW;

ANOXIA; CYTOTOXINS; GENE THERAPY; HUMANS; NEOPLASMS; PRODRUGS; RADIATION-SENSITIZING AGENTS;

EID: 34347212864     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2329     Document Type: Review

References (225)

1. Thomlinson, R. H., and L. H. Gray: The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9, 539-549 (1955)
2. Brown, J. M.: Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52, 650-656 (1979) (Pubitemid 9239867)
3. Brown, J. M., and A. J. Giaccia: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58, 1408-1416 (1998) (Pubitemid 28193601)
4. Chaplin, D. J., R. E. Durand, and P. L. Olive: Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys 12, 1279-1282 (1986) (Pubitemid 16030598)
5. Trotter, M. J., D. J. Chaplin, and P. L. Olive: Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer 59, 706-709 (1989) (Pubitemid 19148529)
6. Kimura, H., R. D. Braun, E. T. Ong, R. Hsu, T. W. Secomb, D. Papahadjopoulos, K. Hong, and M. W. Dewhirst: Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 56, 5522-5528 (1996) (Pubitemid 27011389)
7. Hill, S. A., K. H. Pigott, M. I. Saunders, M. E. Powell, S. Arnold, A. Obeid, G. Ward, M. Leahy, P. J. Hoskin, and D. J. Chaplin: Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer 27 Suppl, S260-S263 (1996) (Pubitemid 26237974)
8. Brown, J. M., and W. R. Wilson: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4, 437-447 (2004) (Pubitemid 38745529)
9. Nordsmark, M., M. Overgaard, and J. Overgaard: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41, 31-39 (1996) (Pubitemid 26396294)
10. Brizel, D. M., G. S. Sibley, L. R. Prosnitz, R. L. Scher, and M. W. Dewhirst: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38, 285-289 (1997) (Pubitemid 27318643)
11. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26, 45-50 (1993) (Pubitemid 23063609)
12. Fyles, A. W., M. Milosevic, M. Pintilie, and R. P. Hill: Cervix cancer oxygenation measured following external radiation therapy. Int J Radiat Oncol Biol Phys 42, 751-753 (1998) (Pubitemid 28559411)
13. Durand, R. E.: The influence of microenvironmental factors during cancer therapy. In vivo 8, 691-702 (1994)
14. Kennedy, A. S., J. A. Raleigh, G. M. Perez, D. P. Calkins, D. E. Thrall, D. B. Novotny, and M. A. Varia: Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 37, 897-905 (1997) (Pubitemid 27181324)
15. Semenza, G. L.: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721-732 (2003) (Pubitemid 37328811)
16. Forsythe, J. A., B. H. Jiang, N. V. Iyer, F. Agani, S. W. Leung, R. D. Koos, and G. L. Semenza: Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 16, 4604-4613 (1996) (Pubitemid 26272112)
17. Carmeliet, P., Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, C. J. Koch, P. Ratcliffe, L. Moons, R. K. Jain, D. Collen, and E. Keshert: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998) (Pubitemid 28373960)
18. Erler, J. T., K. L. Bennewith, M. Nicolau, N. Dornhofer, C. Kong, Q. T. Le, J.-T. A. Chi, S. S. Jeffrey, and A. J. Giaccia: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440, 1222-1226 (2006)
19. Carmeliet, P.: VEGF as a key mediator of angiogenesis in cancer. Oncology 69, 4-10 (2005) (Pubitemid 41680947)
20. Brizel, D. M., S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean, L. R. Prosnitz, and M. W. Dewhirst: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 56, 941-943 (1996) (Pubitemid 26065381)
21. Hockel, M., K. Schlenger, B. Aral, M. Mitze, U. Schaffer, and P. Vaupel: Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56, 4509-4515 (1996) (Pubitemid 26330463)
22. Watson, E. R., K. E. Halnan, S. Dische, M. I. Saunders, I. S. Cade, J. B. McEwen, G. Wiernik, D. J. D. Perrins, and I. Sutherland: Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 51, 879-887 (1978) (Pubitemid 9033490)
23. Dische, S., P. J. Anderson, R. Sealy, and E. R. Watson: Carcinoma of the cervix: anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 56, 251-255 (1983) (Pubitemid 13119078)
24. Henk, J. M.: Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell radiosensitizers. Int J Radiat Oncol Biol Phys 12, 1339-1341 (1986) (Pubitemid 16030612)
25. Rockwell, S.: Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res 9, 383-390 (1997) (Pubitemid 127825992)
26. Horsman, M. R., D. J. Chaplin, and J. M. Brown: Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res 109, 479-489 (1987) (Pubitemid 17059700)
27. Chaplin, D. J., M. R. Horsman, and D. S. Aoki: Nicotinamide, Fluosol DA and carbogen: a strategy to oxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer 63, 109-113 (1991)
28. Kjellen, E., M. C. Joiner, J. M. Collier, J. Johns, and A. Rojas: A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother Oncol 22, 81-91 (1991)
29. Corry, J., and D. Rischin: Strategies to overcome accelerated repopulation and hypoxia-what have we learned from clinical trials? Semin Oncol 31, 802-808 (2004) (Pubitemid 39602686)
30. Jirtle, R.: Chemical modification of tumour blood flow. Int J Hyperthermia 4, 355-371 (1988)
31. Teicher, B. A., and C. M. Rose: Oxygen-carrying perfluorochemical emulsion as an adjuvant to radiation therapy in mice. Cancer Res 44, 4285-4288 (1984) (Pubitemid 14008736)
32. Rockwell, S., T. P. Mate, C. G. Irvin, and M. Nierenburg: Reactions of tumors and normal tissues in mice to irradiation in the presence and absence of a perfluorochemical emulsion. Int J Radiat Oncol Biol Phys 12, 1315-1318 (1986) (Pubitemid 16030607)
33. Hirst, D. G., and P. J. Wood: Altered radiosensitivity in a mouse carcinoma after administration of clofibrate and benzafibrate. Radiother Oncol 15, 55-61 (1989) (Pubitemid 19147620)
34. Choy, H., A. Nabid, B. Stea, C. Scott, W. Roa, L. Kleinberg, J. Ayoub, C. Smith, L. Souhami, S. Hamburg, W. Spanos, H. Kreisman, A. P. Boyd, P. J. Cagnoni, and W. J. Curran: Phase II multicenter study of induction chemotherapy followed by concurrent efaproxiral (RSR13) and thoracic radiotherapy for patients with locally advanced non-small-cell lung cancer. J Clin Oncol 23, 5918-5928 (2005)
35. Song, C. W., H. Park, and R. Griffin: Improvement of tumor oxygenation by mild hyperthermia. Radiat Res 155, 515-528 (2001) (Pubitemid 32260249)
36. Adams, G. E., and M. S. Cooke: Electron-affinic sensitization. I. A structural basis for chemical radiosensitizers in bacteria. Int J Radiat Biol Relat Stud Phys Chem Med 15, 457-471 (1969)
37. Urtasun, R. C., P. Band, J. D. Chapman, M. L. Feldstein, B. Mielke, and C. Fryer: Radiation and high dose metronidazole in supratentorial glioblastomas. N Engl J Med 294, 1364-1367 (1976)
38. Dische, S., M. I. Saunders, M. E. Lee, G. E. Adams, and I. R. Flockhart: Clinical testing of the radiosensitizer Ro 07-0582: Experience with multiple doses. Br J Cancer 35, 567-579 (1977) (Pubitemid 8107820)
39. Dische, S.: Chemical sensitisers for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother Oncol 3, 97-115 (1985) (Pubitemid 15170205)
40. Overgaard, J.: Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res 6, 509-518 (1994)
41. Brown, J. M., N. Y. Yu, D. M. Brown, and W. W. Lee: SR-2508: A 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 7, 695-703 (1981) (Pubitemid 11060951)
42. Smithen, C. E., E. D. Clarke, J. A. Dale, R. S. Jacobs, P. Wardman, M. E. Watts, and M. Woodcock: Novel (nitro-1-imidazolyl) alkanolamines as potential radiosensitisers with improved therapeutic properties. In: Radiation Sensitizers. Their Use in the Clinical Management of Cancer, Eds: L. W. Brady. Masson Publishing Inc., New York, p. 22-32 (1980)
43. Overgaard, J., H. S. Hansen, M. Overgaard, L. Bastholt, A. Berthelsen, L. Specht, B. Lindelov, and K. A. Jorgensen: A randomized double-blind phase III study of nimorazole as a hypoxic radionsensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 46, 135-146 (1998) (Pubitemid 28109172)
44. Overgaard, J., J. G. Eriksen, M. Nordsmark, J. Alsner, and M. R. Horsman: Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6, 757-764 (2005) (Pubitemid 41430716)
45. Horsman, M. R., L. Bohm, G. P. Margison, L. Milas, J.-F. Rosier, G. Safrany, E. Selzer, M. Verheij, and J. H. Hendry: Tumor radiosensitizers - Current status of development of various approaches: report of an international atomic energy agency meeting. Int J Radiat Oncol Biol Phys 64, 551-561 (2006) (Pubitemid 43083445)
46. Chapman, J. D., J. A. Raleigh, L. Pederson, J. Ngan, F. Y. Shum, B. E. Meeker, and R. C. Urtasun (1979). Potentially three distinct roles for hypoxic cell radiosensitizers in the clinic. Proc 6th Int Congr Radiat Res pp. 885-892. Tokyo.
47. Stratford, I. J.: Mechanisms of hypoxic cell radiosensitizers and the development of new sensitizers. Int J Radiat Oncol Biol Phys 8, 391-398 (1982) (Pubitemid 12090543)
48. Adams, G. E., I. Ahmed, P. W. Sheldon, and I. J. Stratford: Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 49, 571-577 (1984) (Pubitemid 14101679)
49. Hill, R. P., S. Gulyas, and G. F. Whitmore: Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br J Cancer 53, 743-751 (1986) (Pubitemid 16082030)
50. Roberts, P. B., R. F. Anderson, and W. R. Wilson: Hypoxia-selective radiosensitization of mammalian cells by nitracrine, an electron-affinic DNA intercalator. Int J Radiat Biol Relat Stud Phys Chem Med 51, 641-654 (1987) (Pubitemid 17081459)
51. Wilson, W. R., W. A. Denny, G. M. Stewart, A. Fenn, and J. C. Probert: Reductive metabolism and hypoxiaselective toxicity of nitracrine. Int J Radiat Oncol Biol Phys 12, 1235-1238 (1986) (Pubitemid 16055892)
52. Cowan, D. S., R. Panicucci, R. A. McClelland, and A. M. Rauth: Targeting radiosensitizers to DNA by attachment of an intercalating group: nitroimidazole-linked phenanthridines. Radiat Res 127, 81-89 (1991)
53. Papadopoulou, M. V., M. W. Epperly, D. S. Shields, and W. D. Bloomer: Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two bioreductive compounds. Jpn J Cancer Res 83, 410-414 (1992)
54. Denny, W. A., P. B. Roberts, R. F. Anderson, J. M. Brown, D. Phil, and W. R. Wilson: NLA-1: A 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int J Radiat Oncol Biol Phys 22, 553-556 (1992)
55. Denekamp, J., and F. A. Stewart: Sensitization of mouse tumours using fractionated X-irradiation. Br J Cancer 37, 259-263 (1978) (Pubitemid 8363760)
56. Hill, R. P., and R. S. Bush: The effect of misonidazole in combination with radiation dose fractionation. Br J Cancer 37, 255-258 (1978) (Pubitemid 8363759)
57. Sheldon, P. W., and J. F. Fowler: Radiosensitization by misonidazole (Ro-07-0582) of fractionated X-rays in murine tumour. Br J Cancer 37, 243-245 (1978)
58. Brown, J. M., and N. Y. Yu: Radiosensitization of hypoxic cells in vivo by SR 2508 at low radiation doses: A preliminary report. Int J Radiat Oncol Biol Phys 10, 1207-1212 (1984) (Pubitemid 14029864)
59. Wouters, B. G., and J. M. Brown: Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy. Radiat Res 147, 541-550 (1997) (Pubitemid 27204090)
60. Brown, J. M.: The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 59, 5863-5870 (1999) (Pubitemid 30004940)
61. Sutherland, R. M.: Selective chemotherapy of noncycling cells in an in vitro tumor model. Cancer Res 34, 3501-3503 (1974)
62. Hall, E. J., and L. Roizon-Towle: Hypoxic radiosensitisers: radiobiological studies at the cellular level. Radiology 117, 453-457 (1975)
63. Mason, R. P., and J. L. Holtzman: The mechanism of microsomal and mitochondrial nitroreductase. Biochemistry 14, 1626-1632 (1975)
64. Biaglow, J. E., M. E. Varnes, C. J. Koch, and R. Sridhar: Metabolic activation of carcinogenic nitro-compounds to oxygen reactive intermediates. In: Free radicals and Cancer, Eds: R. A. Floyd. Marcel Dekker, New York, (1982)
65. Wardman, P., M. F. Dennis, S. A. Everett, K. B. Patel, M. R. Stratford, and M. Tracy: Radicals from one-electron reduction of nitro compounds, aromatic N-oxides and quinones: The kinetic basis of hypoxia-selective, bioreductive drugs. Biochem Soc Symp 61, 171-194 (1995)
66. Wardman, P.: Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 8, 739-761 (2001) (Pubitemid 32427904)
67. Denny, W. A., and W. R. Wilson: Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met Rev 12, 135-151 (1993) (Pubitemid 23220677)
68. Brown, J. M., and A. Koong: Therapeutic advantage of hypoxic cells in tumors: a theoretical study. J Natl Cancer Inst 83, 178-185 (1991)
69. Rauth, A. M., R. A. McClelland, H. B. Michaels, and R. Battistella: The oxygen dependence of the reduction of nitroimidazoles in a radiolytic model system. Int J Radiat Oncol Biol Phys 10, 1323-1326 (1984) (Pubitemid 14029886)
70. Hay, M. P., W. R. Wilson, J. W. Moselen, B. D. Palmer, and W. A. Denny: Hypoxia-selective antitumor agents. 8. Bis (nitroimidazolyl) alkanecarboxamides: a new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J Med Chem 37, 381-391 (1994) (Pubitemid 24079948)
71. Moselen, J. W., M. P. Hay, W. A. Denny, and W. R. Wilson: N-[2-(2-methyl-5-nitroimidazolyl) ethyl]-4-(2-nitroimidazolyl) butanamide (NSC 639862), a bisnitroimidazole with enhanced selectivity as a bioreductive drug. Cancer Res 55, 574-580 (1995)
72. Papadopoulou, M. V., M. Ji, M. K. Rao, and W. D. Bloomer: 4-[3-(2-nitro-1-imidazolyl) propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine. Oncol Res 12, 325-333 (2000)
73. Papadopoulou, M. V., H. S. Rosenzweig, M. Doddi, and W. D. Bloomer: 9-[3-) 2-nitro-1-imidazolyl) propylamino]-1, 2, 3, 4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol Res 6, 439-448 (1994)
74. Papadopoulou, M. V., M. Ji, and W. D. Bloomer: THNLA-1 as radio/chemosensitiser of EMT-6 tumours in mice. Br J Cancer 74, S267-S270 (1996) (Pubitemid 26237976)
75. Squillace, D. P., S. L. Ruben, J. M. Reid, and M. M. Ames: HPLC analysis and murine pharmacokinetics of the cytotoxic bioreductive agent NLCQ-1 (NSC 709257). Proc Am Assoc Cancer Res 41, 706 (2000)
76. Heimbrook, D. C., and A. C. Sartorelli: Biochemistry of misonidazole by NADPH-cytochrome c (P-450) reductase. Mol Pharmacol 29, 168-172 (1986) (Pubitemid 16165851)
77. Walton, M. I., and P. Workman: Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases in vivo and in vitro. Biochem Pharmacol 36, 887-896 (1987) (Pubitemid 17038036)
78. Hodgkiss, R. J.: Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 13, 687-702 (1998) (Pubitemid 28410155)
79. Perez-Reyez, E., B. Kalyanaraman, and R. P. Mason: The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes. Mol Pharmacol 17, 239-244 (1980) (Pubitemid 10125311)
80. Wardman, P., and E. D. Clarke: Oxygen inhibition of nitroreductase: Electron transfer from nitro radical-anions to oxygen. Biochem Biophys Res Commun 69, 942-949 (1976)
81. Varghese, A. J., S. Gulyas, and J. K. Mohindra: Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl) 3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res 36, 3761-3765 (1976)
82. Flockhart, I. R., P. Large, D. Troup, S. H. Malcolm, and T. R. Marten: Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole. Xenobiotica 8 (1978)
83. McClelland, R. A., J. R. Fuller, N. E. Seaman, A. M. Rauth, and R. Battistella: 2-Hydroxylaminoimidazolesunstable intermediates in the reduction of 2-nitroimidazoles. Biochem Pharmacol 33, 303-309 (1984)
84. Knox, R. J., M. P. Boland, F. Friedlos, B. Coles, C. Southan, and J. J. Roberts: The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4- hydroxylamino-2-nitrobenzamide is a form of NAD (P) H dehydrogenase (quinone) (EC 1.6.99.2). Biochem Pharmacol 37, 4671-4677 (1988) (Pubitemid 19006306)
85. Knox, R. J., F. Friedlos, M. Jarman, and J. J. Roberts: A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2- nitrobenzamide, is formed from 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) by nitroreductase enzyme in Walker carcinoma cells. Biochem Pharmacol 37, 4661 (1988)
86. Walton, M. I., C. R. Wolf, and P. Workman: Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 16, 983-986 (1989) (Pubitemid 19154286)
87. Helsby, N. A., S. J. Wheeler, F. B. Pruijn, B. D. Palmer, S. Yang, W. A. Denny, and W. R. Wilson: Effect of nitroreduction on the alkylating reactivity and cytotoxicity of the 2, 4-dinitrobenzamide-5-aziridine CB1954 and the corresponding nitrogen mustard SN 23862: Distinct mechanisms of bioreductive activation. Chem Res Toxicol 16, 469-478 (2003) (Pubitemid 36514504)
88. Knox, R. J., F. Friedlos, T. Marchbank, and J. J. Roberts: Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem Pharmacol 42, 1691-1697 (1991)
89. Bridgewater, J. A., C. J. Springer, R. J. Knox, N. P. Minton, N. P. Michael, and M. K. Collins: Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 31A, 2362-2370 (1995) (Pubitemid 26053242)
90. Green, N. K., D. J. Youngs, J. P. Neoptolemos, F. Friedlos, R. J. Knox, C. J. Springer, G. M. Anlezark, N. P. Michael, R. G. Melton, M. J. Ford, L. S. Young, D. J. Kerr, and P. F. Searle: Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 4, 229-238 (1997) (Pubitemid 127667119)
91. Chung-Faye, G., D. Palmer, D. Anderson, J. Clark, M. Downes, J. Baddeley, S. Hussain, P. I. Murray, P. Searle, L. Seymour, P. A. Harris, D. Ferry, and D. J. Kerr: Virusdirected, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 7, 2662-2668 (2001) (Pubitemid 32911369)
92. Dachs, G. U., J. Tupper, and G. M. Tozer: From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anti-Cancer Drugs 16, 349-359 (2005) (Pubitemid 40434601)
93. Siim, B. G., W. A. Denny, and W. R. Wilson: Nitro reduction as an electronic switch for bioreductive drug activation. Oncol Res 9, 357-369 (1997) (Pubitemid 127825990)
94. Palmer, B. D., P. van Zijl, W. A. Denny, and W. R. Wilson: Reductive chemistry of the novel hypoxia-selective cytotoxin 5-[N, N-bis (2-chloroethyl) amino]-2, 4-dinitrobenzamide. J Med Chem 38, 1229-1241 (1995)
95. Anlezark, G. M., R. G. Melton, R. F. Sherwood, W. R. Wilson, W. A. Denny, B. D. Palmer, R. J. Knox, F. Friedlos, and A. Williams: Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 50, 609-618 (1995)
96. Wilson, W. R., S. M. Pullen, A. Hogg, N. A. Helsby, K. O. Hicks, and W. A. Denny: Quantitation of bystander effects in nitroreductase suicide gene therapy using threedimensional cell cultures. Cancer Res 62, 1425-1432 (2002) (Pubitemid 34407802)
97. Helsby, N. A., D. M. Ferry, A. V. Patterson, S. M. Pullen, and W. R. Wilson: 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 90, 1084-1092 (2004) (Pubitemid 38495832)
98. Douglas, R. S., A. V. Patterson, S. Yang, W. R. Wilson, and B. G. Siim (2005). Induction of DNA damage and repair responses by the hypoxia-activated prodrug PR-104. AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Philadelphia.
99. Dorie, M. J., G. O. Ahn, D. Menke, R. S. Douglas, B. G. Siim, A. V. Patterson, W. R. Wilson, and J. M. Brown (2006). Prediction of antitumor activity of PR-104, a new hypoxia activated mustard, using measurements of DNA interstrand crosslinks by the Comet assay. American Association for Cancer Research. Washington D. C.
100. Wilson, W. R., S. J. Edmunds, S. Valentine, Y. Gu, H. Myint, K. O. Hicks, S. Yang, G. J. Atwell, W. A. Denny, and A. V. Patterson (2005). Mechanism of action and antitumour activity of PR-104, a dinitrobenzamide mustard pre-prodrug that is activated selectively under hypoxia. National Cancer Research Institute Conference. Birmingham.
101. Stratford, I. J., J. M. Walling, and A. R. J. Silver: The differential toxicity of RSU 1069: Cell survival studies indicating interaction with DNA as possible mode of action. Br J Cancer 53, 339-344 (1986) (Pubitemid 16133103)
102. Whitmore, G. F., and S. Gulyas: Studies on the toxicity of RSU-1069. Int J Radiat Oncol Biol Phys 12, 1219-1222 (1986) (Pubitemid 16055888)
103. Horwich, A., S. B. Holliday, J. M. Deacon, and M. J. Peckham: A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitizer RSU-1069. Br J Radiol 59, 1238-1240 (1986) (Pubitemid 17223261)
104. Jenkins, T. C., M. A. Naylor, P. O'Neill, M. D. Threadgill, S. Cole, I. J. Stratford, G. E. Adams, E. M. Fielden, M. J. Suto, and M. A. Stier: Synthesis and evaluation of alpha-[[(2-haloethyl) amino]methyl]-2-nitro-1H-imidazole-1- ethanols as prodrugs of alpha-[[(2-aziridinyl) methyl]2-nitro-1H-imidazole-1- ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33, 2603-2610 (1990) (Pubitemid 20274220)
105. Cole, S., I. J. Stratford, G. E. Adams, E. M. Fielden, and T. C. Jenkins: Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res 124, S38-S43 (1990)
106. Breider, M. A., G. D. Pilcher, M. J. Graziano, and A. W. Gough: Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer. Toxicol Pathol 26, 234-239 (1998) (Pubitemid 28155329)
107. Parker, R. F., P. W. Vincent, and W. L. Elliot: Alkylating property of nitro-imidazole radiosensitizers is required for induction of murine retinal degeneration. Vet Pathol 33, 625 (1996)
108. Rockwell, S., K. A. Kennedy, and A. C. Sartorelli: Mitomycin C as a prototype bioreductive alkylating agent: in vitro studies of metabolism and cytotoxicity. Int J Radiat Oncol Biol Phys 8, 753-755 (1982) (Pubitemid 12090624)
109. Fracasso, P. M., and A. C. Sartorelli: Cytotoxicity and DNA lesions produced by mitomycin C and porfiromycin in hypoxic and aerobic EMT6 and Chinese hamster ovary cells. Cancer Res 46, 3939-3944 (1986) (Pubitemid 16075888)
110. Iyer, N. V., and W. Szybalski: Mitomycins and porfiromycin: Chemical mechanisms of activation and cross-linking of DNA. Microbiology 50, 355-362 (1963)
111. Tomasz, M., R. Lipman, D. Chowdary, J. Pawlak, G. L. Verdine, and K. Nakanishi: Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235, 1204-1208 (1987) (Pubitemid 17034007)
112. Volpato, M., J. Seargent, P. M. Loadman, and R. M. Phillips: Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity. Eur J Cancer 41, 1331-1338 (2005) (Pubitemid 40813011)
113. Pan, S. S., P. A. Andrews, C. J. Glover, and N. R. Bachur: Reductive activation of mitomycin C and mitomycin C metabolites catalysed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 259, 959-966 (1984) (Pubitemid 14192450)
114. Keyes, S. R., P. M. Fracasso, D. C. Heimbrook, S. Rockwell, S. G. Sligar, and A. C. Sartorelli: Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res 44, 5638-5643 (1984) (Pubitemid 15183570)
115. Bachur, N. R., S. L. Gordon, and M. V. Gee: A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 38, 1745-1750 (1978) (Pubitemid 8349723)
116. Bachur, N. R., S. L. Gordon, M. V. Gee, and H. Kon: NADPH-cyrochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci U S A 76, 954-957 (1979) (Pubitemid 9130981)
117. Pritsos, C. A., and A. C. Sartorelli: Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res 46, 3528-3532 (1986) (Pubitemid 16096902)
118. Iyanagi, T., and I. Yamazaki: One-electron reactions in biochemical systems. V. Differences in the mechanism of quinone reduction by the NADP dehydrogenase and the HAD (P) H dehydrogenase (DT-diaphorase). Biochim Biophys Acta 216, 282-294 (1970)
119. Rockwell, S., and K. A. Kennedy: Combination therapy with radiation and mitomycin C: Preliminary results with EMT6 tumor cells in vitro and in vivo. Int J Radiat Oncol Biol Phys 5, 1673-1676 (1979) (Pubitemid 10130815)
120. Weissberg, J. B., Y. H. Son, R. J. Papac, C. T. Sasaki, D. B. Fischer, R. Lawrence, S. Rockwell, A. C. Sartorelli, and J. J. Fischer: Randomized clinical trial of mitomycin C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 17, 3-9 (1989) (Pubitemid 19173231)
121. Haffty, B. G., Y. H. Son, C. T. Sasaki, R. Papac, D. Fischer, S. Rockwell, A. C. Sartorelli, and J. J. Fischer: Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 27, 241-250 (1993) (Pubitemid 23304449)
122. Haffty, B. G., Y. H. Son, R. Papac, C. T. Sasaki, J. B. Weissberg, D. Fischer, S. Rockwell, A. C. Sartorelli, and J. J. Fischer: Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale Mitomycin Randomized Trials. J Clin Oncol 15, 268-276 (1997) (Pubitemid 27020583)
123. Roberts, K. B., N. Urdaneta, R. Vera, A. Vera, E. Gutierrez, Y. Aguilar, S. Ott, I. Medina, P. Sempere, S. Rockwell, A. C. Sartorelli, D. B. Fischer, and J. J. Fischer: Interim results of a randomized trial of mitomycin C as an adjunct to radical radiotherapy in the treatment of locally advanced squamous-cell carcinoma of the cervix. Int J Cancer 90, 206-223 (2000)
124. Saarilahti, K., M. Kajanti, T. Atula, A. Makitie, L.-M. Aaltonen, M. Kouri, and M. Mantyla: Biweekly escalated, accelerated hyperfractionated radiotherapy with concomitant single-dose mitomycin C results in a high rate of local control in advanced laryngeal and hypopharyngeal cancer. Am J Clin Oncol 27, 589-594 (2004) (Pubitemid 39603274)
125. Rockwell, S., S. R. Keyes, and A. C. Sartorelli: Preclinical studies of porfiromycin as adjunct to radiotherapy. Radiat Res 116, 100-113 (1988)
126. Keyes, S. R., S. Rockwell, and A. C. Sartorelli: Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cells in vivo and in vitro. Cancer Res 45, 3642-3645 (1985) (Pubitemid 15226438)
127. Haffty, B. G., L. D. Wilson, Y. H. Son, E. I. Cho, R. J. Papac, D. B. Fischer, S. Rockwell, A. C. Sartorelli, D. A. Ross, C. T. Sasaki, and J. J. Fischer: Concurrent chemoradiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 61, 119-128 (2005) (Pubitemid 40039113)
128. Oostveen, E. A., and W. N. Speckamp: Mitomycin analogs. I. Indoloquinones as (potential) bisalkylating agents. Tetrahedron 43, 255-262 (1987) (Pubitemid 17227832)
129. Maliepaard, M., A. Wolfs, S. E. Groot, N. J. de Mol, and L. H. M. Janssen: Indoloquinone EO9: DNA interstrand cross-linking upon reduction by DT-diaphorase or xanthine oxidase. Br J Cancer 71, 836-839 (1995)
130. Plumb, J. A., M. Gerritsen, and P. Workman: DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 70, 1136-1143 (1994) (Pubitemid 24358951)
131. Bailey, S. M., A. D. Lewis, L. H. Patterson, G. R. Fischer, and P. Workman: Free radical generation following reduction of EO9: Involvement in cytotoxicity. Br J Cancer 67, 8 (1993)
132. Schellens, J. H. M., A. S. T. Planting, B. A. C. van Acker, W. J. Loos, M. de Boer-Denert, M. E. L. van der Burg, I. Koier, R. T. Krediet, G. Stoter, and J. Verweij: Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 86, 906-912 (1994) (Pubitemid 24177304)
133. Dirix, L. Y., F. Tonnesen, J. Cassidy, R. Epelbaum, W. W. Bokkel Huinink, N. Pavlidis, R. Sorio, T. Gamucci, I. Wolff, V. A. Te, J. Lan, and J. Verweij: EO9 Phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 32A, 2019-2022 (1996) (Pubitemid 26361700)
134. Phillips, R. M.: Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione]prop-beta-en- alpha-ol (EO9) by human DT-diaphorase. Biochem Pharmacol 52, 1711-1718 (1996) (Pubitemid 26407986)
135. Workman, P., and I. J. Stratford: The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Met Rev 12, 73-82 (1993) (Pubitemid 23220673)
136. Fisher, G. R., J. Donis, and P. L. Gutierrez: Reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells. Biochem Pharmacol 44, 1625-1635 (1992)
137. Nemeikaite-Ceniene, A., J. Sarlauskas, Z. Anusevicius, H. Nivinskas, and N. Cenas: Cytotoxicitiy of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD (P) H:quinone oxidoreductase (NQO1) and oxidative stress. Arch Biochem Biophys 416, 110-118 (2003) (Pubitemid 36818854)
138. Winski, S. L. R., R. H. J. Hargreaves, J. Butler, and D. Ross: New screening system for NAD (P) H:quinone oxidoreductase (NQO1)-directed antitumour quinones: The identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumour agent. Clin Cancer Res 4, 3083-3088 (1998) (Pubitemid 29001485)
139. Hargreaves, R. H. J., J. A. Hartley, and J. Butler: Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones. Front Biosci 5, e172-180 (2000)
140. Dehn, D. L., S. H. Inayat-Hussain, and D. Ross: RH1 induces cellular damage in an NAD (P) H:quinone oxidoreductase 1-dependent manner: Relationship between DNA cross-linking, cell cycle perturbations, and apoptosis. J Pharmacol Exp Ther 313, 771-779 (2005) (Pubitemid 40604178)
141. Danson, S., T. H. Ward, J. Butler, and M. Ranson: DT-diaphorase: a target for new anticancer drugs. Cancer Treat Rev 30, 437-449 (2004) (Pubitemid 38968124)
142. Lloyd, R. V., D. R. Duling, G. V. Rumyantseva, R. P. Mason, and P. K. Bridson: Microsomal reduction of 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide to a free radical. Mol Pharmacol 40, 440-445 (1991)
143. Anderson, R. F., S. S. Shinde, M. P. Hay, S. A. Gamage, and W. A. Denny: Activation of 3-amino-1, 2, 4-benzotriazine 1, 4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J Am Chem Soc 125, 748-756 (2003) (Pubitemid 36109936)
144. Baker, M. A., E. M. Zeman, V. K. Hirst, and J. M. Brown: Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res 48, 5947-5952 (1988) (Pubitemid 18266781)
145. Hicks, K. O., F. B. Pruijn, J. R. Sturman, W. A. Denny, and W. R. Wilson: Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellualr layer cultures. Cancer Res 63, 5970-5977 (2003) (Pubitemid 37187499)
146. Walton, M. I., and P. Workman: Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice. J Pharmacol Exp Ther 265, 938-947 (1993) (Pubitemid 23315608)
147. Grahams, M. A., S. Senan, H. J. Robin, N. Eckhardt, D. Lendrem, J. Hinks, D. Greenslade, R. Rampling, S. B. Kaye, R. von Roemeling, and P. Workman: Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial. Cancer Chemother Pharmacol 40, 1-10 (1997) (Pubitemid 27160953)
148. Riley, R. J., and P. Workman: Enzymology of the reduction of the potent benzotriazine-di-N-oxide hypoxic cell cytotoxin SR 4233 (WIN 59075) by NAD (P) H: (quinone acceptor) oxidoreductase (EC 1.6.99.2) purified from Walker 256 rat tumour cells. Biochem Pharmacol 43, 167-174 (1992)
149. Brown, J. M., and L. H. Wang: Tirapazamine: laboratory data relevant to clinical activity. Anticancer Drug Des 13, 529-539 (1998) (Pubitemid 28410147)
150. Koch, C. J.: Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 53, 3992-3997 (1993) (Pubitemid 23267700)
151. Hicks, K. O., B. G. Siim, F. B. Pruijn, and W. R. Wilson: Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors. Radiat Res 161, 656-666 (2004) (Pubitemid 39149574)
152. Zeman, E. M., J. M. Brown, M. J. Lemmon, V. K. Hirst, and W. W. Lee: SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12, 1239-1242 (1986) (Pubitemid 16055893)
153. Beidermann, K. A., J. Wang, R. P. Graham, and J. M. Brown: SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br J Cancer 63, 358-362 (1991)
154. Wang, J., K. A. Biedermann, and J. M. Brown: Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 52, 4473-4477 (1992)
155. Siim, B. G., P. Van Zijl, and J. M. Brown: Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 73, 952-960 (1996) (Pubitemid 26116748)
156. Walton, M. I., C. R. Wolf, and P. Workman: The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233, WIN 59075) by mouse liver. Biochem Pharmacol 44, 251-259 (1992)
157. Wang, J., K. A. Biedermann, C. R. Wolf, and J. M. Brown: Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br J Cancer 67, 321-325 (1993) (Pubitemid 23049556)
158. Riley, R. J., S. A. Hemingway, M. A. Graham, and P. Workman: Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1, 2, 4-benzotriazine-1, 4-di-N-oxide (tirapazamine, SR 4233, WIN 59075). Biochem Pharmacol 45, 1065-1077 (1993) (Pubitemid 23079984)
159. Cahill, A., and I. N. White: Reductive metabolism of 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233) and the induction of unschedules DNA synthesis in rat and human derived cell lines. Carcinogenesis 11, 1407-1411 (1990) (Pubitemid 20245718)
160. Patterson, A. V., H. M. Barham, E. C. Chinje, G. E. Adams, A. L. Harris, and I. J. Stratford: Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br J Cancer 72, 1144-1150 (1995)
161. Patterson, A. V., M. P. Saunders, E. C. Chinje, D. A. Talbot, A. L. Harris, and I. J. Stratford: Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br J Cancer 76, 1338-1347 (1997) (Pubitemid 27474977)
162. Laderoute, K., P. Wardman, and A. M. Rauth: Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1, 2, 4-benzotriazine-1, 4-dioxide (SR 4233). Biochem Pharmacol 37, 1487-1495 (1988) (Pubitemid 18093342)
163. Evans, J. W., K. Yudoh, Y. M. Delahoussaye, and J. M. Brown: Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res 58, 2098-2101 (1998) (Pubitemid 28232893)
164. Delahoussaye, Y. M., J. W. Evans, and J. M. Brown: Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem Pharmacol 62, 1201-1209 (2001) (Pubitemid 33055624)
165. Peters, K. B., H. Wang, J. M. Brown, and G. Iliakis: Inhibition of DNA replication by tirapazamine. Cancer Res 61, 5425-5431 (2001) (Pubitemid 32694922)
166. Peters, K. B., and J. M. Brown: Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res 62, 5248-5253 (2002) (Pubitemid 35024598)
167. Brown, J. M., and M. J. Lemmon: Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res 50, 7745-7749 (1990)
168. Dorie, M. J., and J. M. Brown: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53, 4633-4636 (1993) (Pubitemid 23304391)
169. Rodriguez, G. I., M. Valdivieso, D. D. Von Hoff, M. Kraut, H. A. Burris, J. R. Eckardt, G. Lockwood, H. Kennedy, and R. von Roemeling: A Phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 15, 382 (1996)
170. Miller, V. A., Ng, K. K., Grant, S. C., Kindler, H., Pizzo, B., Heelan, R. T., von Roemeling, R., Kris, M. G.: Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 8, 1269-1271 (1997) (Pubitemid 28164084)
171. Treat, J., Johnson, E., Langer, C., Belani, C., Haynes, B., Greenberg, R., Rodriguez, R., Drobins, P., Miller, W. Jr., Meehan, L., McKeon, A., Devin, J., von Roemeling, R., Viallen, R.: Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 16, 3524-3527 (1998) (Pubitemid 28506763)
172. von Powel, J., von Roemeling, R., Gatzemeier, U., Boyer, M., Elisson, L. O., Clark, P., Talbot, S., Rey A., Butler, T. W., Hirsh, V., Olver, I., Bergman, B., Ayoub, J., Richardson, G., Dunlop, D., Arcenas, A., Vescio, R., Viallet, J., Treat, J.: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. J Clin Oncol 18, 1351-1359 (2000) (Pubitemid 30159856)
173. Rischin, D., L. Peters, R. Hicks, P. Hughes, R. Fisher, R. Hart, M. Sexton, I. D'Costa, and R. von Roemeling: Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 19, 535-542 (2001) (Pubitemid 32112868)
174. Rischin, D., Peters, L., Fisher, R., Macann, A., Danham, J., Poulsen, M., Jackson, M., Kenny, L., Penniment, M., Corry, J., Lamb, D., McClure, B.: Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the trans-Tasman radiation oncology group (TROG 98.02). J Clin Oncol 23, 79-87 (2005) (Pubitemid 41702625)
175. Wilson, W. R., P. Van Zijl, and W. A. Denny: Bisbioreductive agents as hypoxia-selective cytotoxins: nitracrine N-oxide. Int J Radiat Oncol Biol Phys 22, 693-696 (1992)
176. Lee, H. H., W. R. Wilson, D. M. Ferry, P. Van Zijl, S. M. Pullen, and W. A. Denny: Hypoxia-selective antitumour agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine N-oxide. J Med Chem 39, 2508-2517 (1996)
177. Patterson, L. H.: Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent. Cancer Met Rev 12, 119-134 (1993) (Pubitemid 23220676)
178. Smith, P. J., R. Desnoyers, N. Blunt, Y. Giles, L. H. Patterson, and J. V. Watson: Flow cytometric analysis and confocal imaging of the anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation. Cytometry 27, 43-53 (1997) (Pubitemid 27059781)
179. Smith, P. J., N. J. Blunt, R. Desnoyers, Y. Giles, and L. H. Patterson: DNA topoisomerase II-dependent cytotoxicity of alkyklaminoanthraquinones and their N-oxides. Cancer Chemother Pharmacol 39, 455-461 (1997) (Pubitemid 27078132)
180. Patterson, L. H., M. R. Craven, G. R. Fisher, and P. Teesdale-Spittle: Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol Res 6, 533-538 (1994)
181. Patterson, L. H., S. R. McKeown, T. Robson, R. Gallagher, S. M. Raleigh, and S. Orr: Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 14, 473-486 (1999) (Pubitemid 30258967)
182. Patterson, L. H., and S. R. McKeown: AQ4N: a new approach to hypoxia-activated cancer chemotherapy. Br J Cancer 83, 1589-1593 (2000) (Pubitemid 32001698)
183. Patterson, L. H., S. R. McKeown, K. Ruparelia, J. A. Double, M. C. Bibby, S. Cole, and I. J. Stratford: Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer 82, 1984-1990 (2000) (Pubitemid 30326460)
184. Raleigh, S. M., E. Wanogho, M. D. Burke, and L. H. Patterson: Rat cytochromes P450 (CYP) specifically contribute to the reductive bioactivation of AQ4N, an alkylaminoanthraquinone-di-N-oxide anticancer drug. Xenobiotica 29, 1115-1122 (1999)
185. Raleigh, S. M., E. Wanogho, M. D. Burke, S. R. McKeown, and L. H. Patterson: Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Int J Radiat Oncol Biol Phys 42, 763-767 (1998) (Pubitemid 28559413)
186. McKeown, S. R., M. V. Hejmadi, I. A. McIntyre, J. J. McAleer, and L. H. Patterson: AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 72, 76-81 (1995)
187. McKeown, S. R., O. P. Friery, I. A. McIntyre, M. V. Hejmadi, L. H. Patterson, and D. G. Hirst: Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation. Br J Cancer 27 Suppl, S39-S42 (1996) (Pubitemid 26237924)
188. Wilson, W. R., W. A. Denny, S. M. Pullen, K. M. Thompson, A. E. Li, L. H. Patterson, and H. H. Lee: Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br J Cancer 27 Suppl, S43-S47 (1996) (Pubitemid 26237925)
189. Wilson, W. R., J. W. Moselen, S. Cliffe, W. A. Denny, and D. C. Ware: Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt (III)-nitrogen mustard complex SN24771. Int J Radiat Oncol Biol Phys 29, 323-327 (1994) (Pubitemid 24166540)
190. Parker, L. L., Lacy, S. M., Farrugia, L. J., Evans, C., Robins, D. J., O'Hare, C. C., Hartley, J. A., Jaffar, M., Stratford, I. J.: A novel design strategy for stable metal complexes of nitrogen mustards as bioreductive prodrugs. J Med Chem 47, 5683-5689 (2004) (Pubitemid 39447265)
191. Ware, D. C., B. D. Palmer, W. R. Wilson, and W. A. Denny: Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxiaselective cytotoxins. Synthesis and evaluation of cobalt (III) complexes of bidentate mustards. J Med Chem 36, 1839-1846 (1993) (Pubitemid 23203741)
192. Anderson, R. F., W. A. Denny, D. C. Ware, and W. R. Wilson: Pulse radiolysis studies on the hypoxia-selective toxicity of a cobalt-mustard complex. Br J Cancer Suppl. 27, S48-S51 (1996) (Pubitemid 26237926)
193. Ahn, G. O. Investigation of an azachloromethylbenzindoline cobalt (III) complex as a hypoxia-activated prodrug for cancer therapy., University of Auckland, Auckland, New Zealand (2003)
194. Schlager, J. J., and G. Powis: Cytosolic NAD (P) H: (quinone-acceptor) oxidoreductase in human normal and tumour tissue: effects of cigarette smoking and alcohol. Int J Cancer 45, 403-409 (1990) (Pubitemid 20087182)
195. Lee, A. E., and W. R. Wilson: Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 163, 50-59 (2000) (Pubitemid 30111976)
196. Siim, B. G., G. J. Atwell, and W. R. Wilson: Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br J Cancer 70, 596-603 (1994) (Pubitemid 24305583)
197. Marshall, R. S., and A. M. Rauth: Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res 48, 5655-5659 (1988)
198. Mulcahy, R. T.: Effect of oxygen on misonidazole chemosensitization and cytotoxicity in vitro. Cancer Res 44, 4409-4413 (1984) (Pubitemid 14008757)
199. Taylor, Y. C., and A. M. Rauth: Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat Res 91, 104-123 (1982) (Pubitemid 12092075)
200. Wilson, W. R., M. Tercel, R. F. Anderson, and W. A. Denny: Radiation-activated prodrugs as hypoxia-selective cytotoxins: model studies with nitroarylmetyl quaternary salts. Anticancer Drug Des 13, 663-685 (1998) (Pubitemid 28410154)
201. Denny, W. A., W. R. Wilson, and M. P. Hay: Recent developments in the design of bioreductive drugs. Br J Cancer Suppl 27, S32-S38 (1996) (Pubitemid 26237923)
202. Tercel, M., A. E. Lee, A. Hogg, R. F. Anderson, H. H. Lee, B. G. Siim, W. A. Denny, and W. R. Wilson: Hypoxiaselective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 44, 3511-3522 (2001) (Pubitemid 32947916)
203. Anderson, R. F., W. A. Denny, W. Li, J. E. Packer, M. Tercel, and W. R. Wilson: Pulse radiolysis studies on the fragmentation of arylmethyl quaternary nitrogen mustards by one-electron reduction in aqueous solution. J Phys Chem 101, 9704-9709 (1997) (Pubitemid 127617212)
204. Rewcastle, G. W., G. J. Atwell, D. Chambers, B. C. Baguley, and W. A. Denny: Potential antitumor agents. 46. Structure-activity relationships for acridine monosubstituted derivatives of the antitumor agent N-[2-(dimethylamino) ethyl]-9-aminoacridine-4-carboxamide. J Med Chem 29, 472-477 (1986) (Pubitemid 16034763)
205. Nishimoto, S. I., H. Hatta, H. Ureshima, and T. Kagiya: 1-(5'-fluoro-6'-hydroxy-5', 6'-dihydrouracil-5'-yl) - 5-fluorouracil, a novel N (1)-C (5)-linked dimer that releases 5-fluorouracil by radiation activation under hypoxic conditions. J Med Chem 35, 2711-2712 (1992)
206. Shibamoto, Y., L. Zhou, H. Hatta, M. Mayuko, and S. Nishimoto: A novel class of antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), that releases 5-fluorouracil upon hypoxic irradiation. Jpn J Cancer Res 91, 433-438 (2000) (Pubitemid 30312696)
207. Shibamoto, Y., Y. Tachi, K. Tanabe, H. Hatta, and S. Nishimoto: In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation. Int J Radiat Biol Phys 58, 397-402 (2004) (Pubitemid 38142464)
208. Shibamoto, Y., L. Zhou, H. Hatta, M. Mori, and S. Nishimoto: In vivo evaluation of a novel antitumor prodrug, 1-(2'-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation. Int J Radiat Biol Phys 49, 407-413 (2001) (Pubitemid 32120237)
209. Ahn, G. O., K. J. Botting, A. V. Patterson, D. C. Ware, M. Tercel, and W. R. Wilson: Radiolytic and cellular reduction of a novel hypoxia-activated cobalt (III) prodrug of a chloromethylbenzindoline DNA minor groove alkylator. Biochem Pharmacol 71, 1683-1694 (2006)
210. Ahn, G., D. C. Ware, K. J. Botting, S. M. Stribbling, K. O. Hicks, and W. R. Wilson: Plasma pharmacokinetics, tissue disposition, and extracellular diffusion properties of the hypoxia-activated prodrug SN 27892, a cobalt (III) complex of a potent DNA minor groove alkylator. Cancer Chemother Pharmacol In preparation (2006)
211. Denny, W. A.: Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotechnol 2003, 48-70 (2003) (Pubitemid 36828274)
212. Greco, O., B. Marples, M. C. Joiner, and S. D. Scott: How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J Cell Physiol 197, 312-325 (2003) (Pubitemid 37487030)
213. Dachs, G. U., A. V. Patterson, J. D. Firth, P. J. Ratcliffe, K. M. S. Townsend, I. J. Stratford, and A. L. Harris: Targeting gene expression to hypoxic tumor cells. Nat Med 3, 515-520 (1997) (Pubitemid 27198648)
214. Semenza, G. L., and G. L. Wang: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12, 5447-5454 (1992)
215. Patterson, A. V., K. J. Williams, R. L. Cowen, M. Jaffar, B. A. Telfer, M. Saunders, R. Airley, D. Honess, A. J. Van der Kogel, C. R. Wolf, and I. J. Stratford: Oxygen-sensitive enzyme prodrug gene therapy for the eradication of radiationresistant solid tumours. Gene Therapy 9, 946-954 (2002) (Pubitemid 34812285)
216. Cowen, R. L., K. J. Williams, E. C. Chinje, M. Jaffar, F. C. D. Sheppard, B. A. Telfer, N. S. Wind, and I. J. Stratford: Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: Reversing tumor resistance and effecting cure. Cancer Res 64, 1396-1402 (2004) (Pubitemid 38235608)
217. Lemmon, M. J., J. H. Elwell, J. K. Brehm, M. L. Mauchline, M. N, N. P. Minton, A. J. Giaccia, and J. M. Brown: Anaerobic bacteria as a gene delivery system to tumors. Proc Am Assoc Cancer Research 35, 374 (1994)
218. Fox, M. E., M. J. Lemmon, M. L. Mauchline, T. O. Davis, A. J. Giaccia, N. P. Minton, and J. M. Brown: Anaerobic bacteria as a delivery system for cancer gene therapy: activation of 5-fluorocytosine by genetically engineered clostridia. Gene Therapy 3, 173-178 (1996) (Pubitemid 26117427)
219. Carey, R. W., J. F. Holland, H. Y. Whang, E. Neter, and B. Bryant: Clostridial oncolysis in man. Eur J Cancer 3, 37-46 (1967)
220. Heppner, F., and J. R. Mose: The liquefaction (oncolysis) of malignant gliomas by a non pathogenic clostridium. Acta Neuro 12, 123-125 (1978) (Pubitemid 8377876)
221. Heppner, F., J. Mose, P. W. Ascher, and G. Walter: Oncolysis of malignant gliomas of the brain. 13th Int Cong Chemother 226, 38-45 (1983)
222. Lemmon, M. L., P. Van Zijl, M. E. Fox, M. L. Mauchline, A. J. Giaccia, N. P. Minton, and J. M. Brown: Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Thrapy 4, 791-796 (1997) (Pubitemid 27380161)
223. Liu, S. C., N. P. Minton, A. J. Giaccia, and J. M. Brown: Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therapy 9, 291-296 (2002) (Pubitemid 34256904)
224. Ahn, G. O., S. C. Liu, D. Menke, M. J. Dorie, and J. M. Brown (2004). Enhanced antitumor activity of 5-FC by genetically engineered anaerobic bacteria C. sporogenes expressing cytosine deaminase when combined with a vascular targeting agent, ZD6126 or DMXAA. 2nd International Conference on Vascular Targeting: Miami, FL.
225. Theys, J., W. Landuyt, S. Nuyts, L. Van Mellaert, A. van Oosterom, P. Lambin, and J. Anne: Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum. Cancer Gene Ther 8, 294-297 (2001) (Pubitemid 32480066)